|drug956||high flow nasal cannula (HFNC) Wiki||1.00|
|drug70||Association of diltiazem and niclosamide Wiki||1.00|
|drug776||Standard of care (SOC) Wiki||1.00|
|D055371||Acute Lung Injury NIH||0.16|
|D012127||Respiratory Distress Syndrome, Newborn NIH||0.15|
|D012128||Respiratory Distress Syndrome, Adult NIH||0.13|
|D014777||Virus Diseases NIH||0.11|
|D045169||Severe Acute Respiratory Syndrome NIH||0.07|
|D018352||Coronavirus Infections NIH||0.06|
There is one clinical trial.
Coronavirus disease 2019 (COVID-19) is an emerging infectious disease that was first reported in Wuhan, China, and had subsequently spread worldwide. Twenty-nine percent of COVID-19 patients may develop ARDS. Based on the potential beneficial mechanisms of HFNC and PP, whether early use of prone positioning combined with HFNC can avoid the need for intubation in COVID-19 induced moderate to severe ARDS patients needs to be further investigated.
Description: the treatment failure rate of HFNC/HFNC+PP support and clinical requirement for advanced respiratory supportMeasure: Treatment failure Time: 28 days
Description: the improvement of SpO2/FIO2 or PaO2/FiO2 from HFNC alone to HFNC+PPMeasure: Efficacy of PP Time: 28 days